Exon-skipping drugs for Duchenne muscular dystrophy represent a critical proving ground for the FDA's stated ambition to accelerate rare disease treatments, yet access remains limited to a fortunate few patients. The mismatch between scientific promise and real-world availability highlights the structural barriers that persist in rare disease care. For specialty pharma, this underscores that regulatory approval is only the first step in a far longer access journey. Stakeholders should watch how payer coverage, mutation-specific eligibility, and site-of-care logistics shape who actually benefits.
Shionogi is acquiring Texas-based IntraBio for $2 billion, adding a marketed treatment for two inherited conditions to its expanding rare disease portfolio. The deal signals continued strategic appetite for rare disease assets with commercial-stage products.
Caribou Biosciences, co-founded by Nobel laureate Jennifer Doudna, is winding down after failing to raise capital for a late-stage trial of its off-the-shelf CAR-T therapy for lymphoma. The closure underscores the funding pressures facing even high-pedigree cell therapy developers.
GE HealthCare is acquiring Sofie Biosciences for $945 million, expanding its capabilities in radiopharmaceuticals used in PET imaging. The deal strengthens manufacturing and distribution of time-sensitive diagnostic and therapeutic agents.
Beam Therapeutics has filed suit against YolTech Therapeutics and Serapha Bio, alleging a former scientist stole confidential base editing information to develop a rival rare disease therapy. Serapha denies the claims.
US tariffs on imported patented medicines and ingredients expanded on September 29 to mid-sized and smaller drugmakers previously excluded from the first company list. Industry groups warn the duties will pressure R&D budgets and supply chains.
The administration is advancing the first government-funded clinical trials of the psychedelic ibogaine to treat opioid addiction and PTSD. The move marks a notable shift in federal support for psychedelic research.
Regulatory approval increasingly marks the beginning, not the end, of the access journey for rare disease therapies. The real determinant of patient impact is whether eligibility verification, payer coverage, and site-of-care logistics align to turn an available therapy into a treated patient. Programs designed around this operational reality will differentiate launches in crowded rare disease categories.
As radiopharmaceuticals and cell therapies move toward the mainstream, delivery timing and coordination become clinical factors in their own right. Access teams must increasingly orchestrate manufacturing, scheduling, and site-of-care as a single integrated workflow rather than sequential handoffs.
Upstream pressures like expanded tariffs and R&D cost inflation rarely stay upstream—they eventually surface as affordability challenges for patients. Forward-looking access programs are stress-testing their financial assistance models now, anticipating that macroeconomic forces will reshape out-of-pocket exposure for specialty therapies.
